Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2930 injection + oxaliplatin + capecitabine + bevacizumab
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
TQB2930 injection + oxaliplatin + capecitabine + bevacizumab is a combination therapeutic regimen being evaluated for the treatment of HER2-positive colorectal cancer. The core component, TQB2930, is a bispecific antibody developed by Chia Tai Tianqing that simultaneously targets two non-overlapping epitopes (ECD2 and ECD4) of the Human Epidermal Growth Factor Receptor 2 (HER2), leading to enhanced receptor internalization and dual signaling blockade. This is combined with the CAPOX chemotherapy regimen—consisting of oxaliplatin (a platinum-based DNA alkylating agent) and capecitabine (an oral fluoropyrimidine carbamate that acts as a thymidylate synthase inhibitor)—and bevacizumab, a monoclonal antibody that inhibits tumor angiogenesis by binding to Vascular Endothelial Growth Factor (VEGF). The regimen is currently in Phase Ib/II clinical development for patients with unresectable locally advanced or metastatic HER2-positive colorectal cancer.
- Other names
- TQB2930 + CAPOX + bevacizumabTQB2930 + oxaliplatin + capecitabine + bevacizumab
02
Targets
TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TQB2930 injection + oxaliplatin + capecitabine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2930 injection + oxaliplatin + capecitabine + bevacizumab.